New York, NY, and Detroit, MI, July 18, 2021 – RMA of Michigan, a Michigan-based, regional leader in advanced fertility care, and Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced that RMA of Michigan has been acquired by affiliates of Albaron. RMA of Michigan will become part of Innovation Fertility, Albaron’s reproductive endocrinology platform. The financial terms of the transaction were not disclosed. Company founder and Chief Medical Officer, Dr. Brad Miller, has retained a minority ownership stake in RMA of Michigan.

Reproductive endocrinology is among the fastest-growing medical specialties in the country. Demand for advanced fertility care will continue to rise as couples are deciding to have children later in life and the prevalence of male infertility, driven by environmental and lifestyle factors, increases. Further trends favoring industry demand are a growing percentage of same-sex couples desiring children and an increasing number of employers offering benefits for IVF and genetic testing services.

“We welcome Dr. Brad Miller and the entire RMA of Michigan team to the Innovation Fertility family. The acquisition brings together two organizations with an unwavering commitment to patient experience and outcomes,” said Albaron Founder and Partner Alessio Baraldi. “The mission of RMA of Michigan has always been to provide personalized fertility care with the highest chances of success. We are thrilled to partner with Albaron and are excited about the operating capabilities and capital resources they provide to complement the strength of our exceptional clinical team,” said Dr. Miller. RMA of Michigan’s commitment to providing a first-class patient experience remains unchanged, and management expects that under the leadership of Innovation Fertility, they will have the flexibility and expertise to focus on what matters most – helping patients build their families.


Based in Detroit, MI, RMA of Michigan is one of the leading fertility clinics in the Midwest. Founded in 2006 by Dr. Bradley Miller, the Company’s three physicians complete around 800 IVF cycles each year. For more information, visit:


Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine some of the premier reproductive endocrinologists of the world with the most experienced laboratory managers and operators in the space, resulting in exceptional medical care and an unparalleled patient experience. For more information, visit:


Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit:


This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for RMA of Michigan following its acquisition by Albaron. If any of these risks or uncertainties materialize, or if any of RMA of Michigan’s or Albaron’s assumptions prove incorrect, RMA of Michigan’s results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to RMA of Michigan and Albaron as of the date of this communication, and RMA of Michigan and Albaron do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.